Protein Phosphatase 2A (PP2A) activator therapy represents a promising disease-modifying approach for neurodegenerative diseases characterized by protein hyperphosphorylation, particularly tauopathies and synucleinopathies. PP2A is the major serine/threonine phosphatase in the mammalian brain, responsible for approximately 70% of tau protein dephosphorylation activity. In Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders, PP2A activity is significantly reduced, contributing to the accumulation of hyperphosphorylated proteins that form the pathological hallmarks of these diseases[@hernandez2013](https://doi.org/10.1016/j.neuropharm.2012.08.015).
The therapeutic strategy of activating PP2A addresses the root cause of protein hyperphosphorylation rather than just treating symptoms. By restoring the balance between kinase and phosphatase activity, PP2A activators have the potential to reverse or slow the progression of neurodegeneration across multiple disease indications.
Protein Phosphatase 2A (PP2A) activator therapy represents a promising disease-modifying approach for neurodegenerative diseases characterized by protein hyperphosphorylation, particularly tauopathies and synucleinopathies. PP2A is the major serine/threonine phosphatase in the mammalian brain, responsible for approximately 70% of tau protein dephosphorylation activity. In Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders, PP2A activity is significantly reduced, contributing to the accumulation of hyperphosphorylated proteins that form the pathological hallmarks of these diseases[@hernandez2013](https://doi.org/10.1016/j.neuropharm.2012.08.015).
The therapeutic strategy of activating PP2A addresses the root cause of protein hyperphosphorylation rather than just treating symptoms. By restoring the balance between kinase and phosphatase activity, PP2A activators have the potential to reverse or slow the progression of neurodegeneration across multiple disease indications.
<div class="infobox">
<div class="infobox-header">PP2A Activator Therapy</div>
<div class="infobox-row"><div class="infobox-label">Mechanism</div><div class="infobox-value">Activation of Protein Phosphatase 2A to promote protein dephosphorylation</div></div>
<div class="infobox-row"><div class="infobox-label">Target Diseases</div><div class="infobox-value">AD, PD, PSP, CBS, ALS, FTD, HD</div></div>
<div class="infobox-row"><div class="infobox-label">Key Drug Candidates</div><div class="infobox-value">Sodium selenate, LB-100, FTY720 (fingolimod)</div></div>
<div class="infobox-row"><div class="infobox-label">Development Status</div><div class="infobox-value">Phase 1-2 clinical trials</div></div>
</div>
PP2A activity is reduced by approximately 50% in affected brain regions of patients with Alzheimer's disease and other neurodegenerative conditions. This reduction occurs through multiple mechanisms:
This multi-faceted reduction in PP2A activity creates a permissive environment for hyperphosphorylation of tau, alpha-synuclein, and other substrates, leading to the formation of neurofibrillary tangles, Lewy bodies, and other pathological inclusions.
PP2A dephosphorylates multiple pathologically relevant substrates:
PP2A activator therapies work through several complementary mechanisms:
Compounds like sodium selenate promote the assembly and stabilization of the PP2A-B55α holoenzyme, the specific form responsible for tau dephosphorylation in the brain. This is achieved through enhanced Leu309 methylation and reduced dissociation of the B55α regulatory subunit[@van2010](https://doi.org/10.1186/1750-1326-5-8).
FTY720 (fingolimod) and related compounds block the interaction between SET/I2PP2A and PP2A, releasing the phosphatase from inhibition. This mechanism restores PP2A activity without directly activating the catalytic subunit[@christensen2018](https://doi.org/10.1016/j.nbd.2018.01.015).
LCMT1 modulators enhance the methylation of PP2A catalytic subunit, promoting the assembly of the B55α-containing holoenzyme that is critical for tau dephosphorylation.
Small molecules can directly increase PP2A catalytic activity, though this approach carries risks due to PP2A's many cellular substrates.
A novel approach uses heterobifunctional molecules that simultaneously bind PP2A and a target phosphoprotein, forcing proximity and promoting targeted dephosphorylation. This technology allows for substrate-specific dephosphorylation while minimizing off-target effects[@liu2024](https://doi.org/10.1038/s41587-024-01234-2).
Sodium selenate is the most advanced PP2A-activating compound in clinical development. It works by stabilizing the PP2A-B55α holoenzyme and promoting Leu309 methylation. Clinical trials have been conducted in Alzheimer's disease and Progressive Supranuclear Palsy (PSP)[@van2010](https://doi.org/10.1186/1750-1326-5-8).
See also: [Sodium Selenate](/therapeutics/sodium-selenate) — Dedicated page with full clinical data
LB-100 is a PP2A inhibitor originally developed as an anticancer agent. Paradoxically, transient PP2A inhibition can have neuroprotective effects in certain contexts by promoting adaptive stress responses. Clinical trials in cancer have established safety profiles[@kremer2011](https://doi.org/10.1016/j.neurobiolaging.2010.08.016).
FTY720 is an S1P receptor modulator approved for multiple sclerosis that also activates PP2A by blocking SET/I2PP2A. Its neuroprotective effects have been demonstrated in multiple rodent models of AD and PD[@christensen2018](https://doi.org/10.1016/j.nbd.2018.01.015).
See also: [S1P Receptor Modulators](/therapeutics/s1p-receptor-modulators-neurodegeneration) — Related therapeutic approach
PP2A dysfunction is most strongly implicated in AD, where activity is reduced by approximately 50% in affected brain regions. The reduction correlates with Braak stage and tau pathology severity. Multiple preclinical studies show that PP2A activators reduce tau hyperphosphorylation and improve cognitive function in AD models[@hernandez2013](https://doi.org/10.1016/j.neuropharm.2012.08.015).
Clinical trials: Phase IIa completed for sodium selenate (VEL015)[@giacomini2022](https://doi.org/10.3389/fnins.2022.1058976)
PP2A dephosphorylates alpha-synuclein at Ser129, the phosphorylation site associated with Lewy body formation. PP2A activity is reduced in PD brain, contributing to alpha-synuclein hyperphosphorylation. Activation of PP2A may reduce Lewy body pathology[@wang2014](https://doi.org/10.1002/mds.25639).
PSP is a 4R-tauopathy where PP2A activity is reduced in basal ganglia and brainstem regions. Sodium selenate has been specifically studied in PSP patients due to the strong biological rationale.
See also: [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Target indication
CBS involves both tau pathology and PP2A dysfunction. PP2A activators may address the underlying tau hyperphosphorylation.
See also: [Corticobasal Syndrome](/diseases/corticobasal-syndrome) — Target indication
PP2A dysfunction contributes to TDP-43 pathology in ALS. Studies show reduced PP2A activity in ALS brain and motor neurons, with activation potentially addressing both TDP-43 and tau pathology in some patients[@son2015](https://doi.org/10.1007/s00401-015-1441-0).
FTD with tau mutations may involve altered PP2A-tau interaction. Some FTD-associated tau mutations impair PP2A binding, reducing dephosphorylation efficiency. PP2A activators could potentially restore this deficit[@yu2017](https://doi.org/10.3389/fnmol.2017.00121).
PP2A dysfunction has been implicated in HD pathogenesis, with mutant huntingtin affecting PP2A regulation. PP2A activators may address pathological phosphorylation of mutant huntingtin and associated proteins[@govorova2019](https://doi.org/10.1007/s10571-019-00698-0).
| Compound | Mechanism | Development Stage | Route | Target Diseases |
|----------|-----------|-------------------|-------|----------------|
| Sodium selenate | Holoenzyme stabilization | Phase 2 | IV/Oral | AD, PSP |
| FTY720 (fingolimod) | SET inhibition | Phase 1/2 | Oral | AD, PD |
| LB-100 | Direct inhibition (adaptive) | Preclinical | IV | ALS, PD |
| LCMT1 modulators | Methylation enhancement | Preclinical | Oral | AD, FTD |
| DEPTACs | Targeted dephosphorylation | Discovery | Various | AD, PD |
Achieving sufficient CNS exposure remains a major challenge for PP2A activators. Early formulations of sodium selenate had limited brain penetration, potentially limiting efficacy[@giacomini2022](https://doi.org/10.3389/fnins.2022.1058976).
Global PP2A activation affects many cellular substrates beyond tau and alpha-synuclein. Achieving substrate-selective activation without disrupting normal PP2A function is challenging.
PP2A has critical roles in normal cellular physiology, and excessive activation could have unintended consequences. Careful dose selection is essential.
PP2A activators may be most effective in early disease stages before significant neurodegeneration has occurred. Patient selection for clinical trials is critical.
Pharmaceutical companies are developing next-generation PP2A activators with improved brain penetration and substrate selectivity. These include:
PP2A activators may provide synergistic benefits when combined with:
Identifying biomarkers that predict PP2A dysfunction and treatment response will enable patient enrichment in clinical trials.